This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A fully caninised anti-NGF monoclonal antibody for pain relief in dogs
BMC Veterinary Research Open Access 09 November 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
07 May 2012
In the version of this article initially published, in Table 1 on p.174, Medi-578 was mistakenly said to be halted in phase 2. In fact, it was stopped in phase 1. The error has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Fate of novel painkiller mAbs hangs in balance. Nat Biotechnol 29, 173–174 (2011). https://doi.org/10.1038/nbt0311-173
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0311-173
This article is cited by
-
The evolution of nerve growth factor inhibition in clinical medicine
Nature Reviews Rheumatology (2021)
-
Pfizer and Lilly shoulder novel pain-drug risks
Nature Biotechnology (2014)
-
Targeting Nerve Growth Factor (NGF) for Pain Management: What Does the Future Hold for NGF Antagonists?
Drugs (2014)
-
A fully caninised anti-NGF monoclonal antibody for pain relief in dogs
BMC Veterinary Research (2013)
-
Erratum: Fate of novel painkiller mAbs hangs in balance
Nature Biotechnology (2012)